FDA clears Atrium Therapeutics 37-patient clinical trial

• Atrium Therapeutics received FDA clearance for its investigational new drug application to begin a 37-participant clinical trial.
• Following the regulatory approval the Atrium Therapeutics share price traded lower in the financial market.
• The company expects to utilize the Phase 1/2 study to evaluate dosage safety and establish clinical proof-of-concept.

Atrium Therapeutics (NASDAQ:RNA) received FDA clearance for its Investigational New Drug application to begin a 37-participant Phase 1/2 clinical trial.

The upcoming Corventis study targets PRKAG2 syndrome, a rare genetic cardiomyopathy that currently lacks any approved therapies addressing its root cause.

The clinical evaluation features an open-label, multicenter design divided into a multiple-ascending-dose phase and a subsequent single-arm expansion cohort.

Management stated that clinical site initiation is actively underway, with the first patient enrollment expected before the end of 2026.

The company continues to prioritize its proprietary ribonucleic acid delivery platform to address previously untreatable cardiovascular diseases.

The business operates as an independent public entity following its recent spin-off from Avidity Biosciences during a $12 billion acquisition by Novartis.